去甲氧柔红霉素联合方案治疗22例难治性、复发性多发性骨髓瘤  

Idarubicin combined chemotherapy regimen for 22 cases with refractory or relapsed multiple myeloma

作　　者：邹外一[1] 罗绍凯[1] 李娟[1] 

机构地区：[1]中山医科大学附属第一医院血液内科,广东广州510080

出　　处：《中国癌症杂志》2002年第1期51-54,共4页China Oncology

摘　　要：目的 :研究VIDM方案 (长春新碱、去甲氧柔红霉素、地塞米松及马法兰 )对难治、复发性多发性骨髓瘤 (MM)的疗效及其毒性反应。方法 :随机将 45例难治、复发MM患者分为两组 :VIDM组 (治疗组 ) 2 2例 ,采用VIDM方案治疗 ,VAD组 (对照组 ) 2 3例 ,采用VAD方案治疗 ,观察疗效及毒性反应。结果 :VIDM组总体有效率(PR +进步 )为 5 9 1%,B组总体有效率为 2 6 1%,两组间有显著性差异 (P <0 0 5 ) :两组间各种主要疗效指标比较 ,VIDM方案明显优于VAD方案 (P <0 0 5 ) :VIDM组骨髓抑制发生率比VAD组高 (P <0 0 5 ) ,但均在停药 2周左右恢复 ,未见永久性造血干细胞损伤 ,无需延长疗程 ;VIDM方案髓外副作用较轻。结论 :VIDM方案治疗MM疗效可靠 ,髓外毒副作用轻 ,骨髓抑制程度亦可接受 ,是目前治疗MM较理想的方法之一 ,因此值得在临床推广应用。Purpose:To study the efficacy and toxicity of VIDM regimen (vincristine,idarubicin,dexamethasone and melphalan) for refractory or relapsed multiple myeloma(MM).Methods:45 refractory or relapsed MM patients were randomized into two groups: VIDM group(treatment group) had 22 patients treated with VIDM regimen, VAD group(control group) had 23 patients with VAD regimen.Results:The effective rate with VIDM regimen (59.1%) was significantly higher than that of VAD regimen (26.1%) (P<0.05). Myelosuppression rate of VIDM was significantly higher than that of VAD regimen,but all patients recovered in about two weeks.Conclusions:VIDM regimen is efficient for refractory or relapsed MM patients, its adverse effects are moderate, and with appropriate supportive management,myelosuppression is tolerable without delay of the next course of chemotherapy.

关 键 词：多发性骨髓瘤 化疗 去甲氧柔红霉素 难治性 复发性 药物联合治疗 

分 类 号：R733.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]